Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Phathom Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
PHAT
Nasdaq
8731
https://www.phathompharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Phathom Pharmaceuticals Inc
MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors
- Apr 19th, 2024 7:03 pm
12 Most Shorted Stocks in 2024
- Apr 19th, 2024 3:02 pm
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
- Apr 5th, 2024 10:30 pm
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- Apr 3rd, 2024 12:00 pm
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
- Mar 26th, 2024 12:00 pm
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2023 Earnings Call Transcript
- Mar 8th, 2024 8:05 pm
Q4 2023 Phathom Pharmaceuticals Inc Earnings Call
- Mar 8th, 2024 6:57 am
Phathom Pharmaceuticals Inc (PHAT) Reports Q4 and Full Year 2023 Financials, Eyes Growth with ...
- Mar 7th, 2024 6:38 pm
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Mar 7th, 2024 1:00 pm
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
- Feb 29th, 2024 1:00 pm
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
- Feb 13th, 2024 1:00 pm
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Jan 31st, 2024 1:00 pm
With 47% ownership, Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) has piqued the interest of institutional investors
- Jan 28th, 2024 12:26 pm
Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
- Dec 14th, 2023 1:00 pm
Several Insiders Invested In Phathom Pharmaceuticals Flagging Positive News
- Dec 14th, 2023 12:01 pm
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
- Dec 6th, 2023 1:00 pm
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
- Nov 28th, 2023 1:00 pm
Phathom Pharmaceuticals Inc (PHAT) Reports Q3 2023 Financial Results
- Nov 9th, 2023 2:34 pm
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
- Nov 9th, 2023 1:00 pm
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
- Nov 1st, 2023 9:00 pm
Scroll